|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Net earned premium | |||||
| Ceding commission income | |||||
| Net investment income | |||||
| Commission and other income | |||||
| Total revenue | |||||
| Expense | |||||
| Loss and loss adjustment expense, net | |||||
| Other insurance expense | |||||
| Sales and marketing | |||||
| Technology development | |||||
| General and administrative | |||||
| Total expense | |||||
| Loss before income taxes | |||||
| Income tax expense (benefit) | |||||
| Net loss | |||||
| Other comprehensive income (loss), net of tax | |||||
| Unrealized gain on investments in fixed maturities | |||||
| Foreign currency translation adjustment | |||||
| Comprehensive loss | |||||
| Per share data: | |||||
| Net loss per share attributable to common stockholders — basic (usd per share) | |||||
| Net loss per share attributable to common stockholders — diluted (usd per share) | |||||
| Weighted average common shares outstanding — basic (in shares) | |||||
| Weighted average common shares outstanding — diluted (in shares) |
Loading...